Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability

Figures & data

Table 1 Severe neuropsychiatric adverse effects in a large open extension study

Aggression	1%
Psychotic disorder, suicidal ideation	0.5%
Affective disorders, depression, suicidal attempt	0.3%
Paranoia, agitation, abnormal behavior, disorientation	0.2%

Notes: Patients were undergoing long-term treatment at a mean PER dose of 10.6 mg/day. Data from Krauss GL et al.³²

KraussGLPeruccaEBen-MenachemELong-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307Epilepsia20145571058106824867391

 PubMed Web of Science ®Google Scholar